Elucidating the exact pharmacological mechanism of motion (MOA) of naturally happening compounds might be tough. Whilst Tarselli et al. (60) produced the first de novo synthetic pathway to conolidine and showcased this naturally occurring compound effectively suppresses responses to equally chemically induced and inflammation-derived pain, the phar